Medications After Liver Transplant: The Immunosuppressants Explained

After a liver transplant you take anti-rejection medicines for life — usually tacrolimus, often with mycophenolate and early steroids, sometimes everolimus. Doses are highest in the first months, then lowered to the smallest amount that protects the graft. Normal liver tests are the medicines working, not a reason to stop; 15–40% of adult recipients do not take them as prescribed, and that is how grafts are lost.
— Dr Chetan Kalal, DM Hepatology, Gleneagles Hospital Mumbai

This article explains what these medicines are and why they matter. It is educational, not a substitute for your transplant team’s specific prescribing guidance. Never start, stop or change any transplant medication without speaking to your transplant team directly.

“My liver tests are normal now — do I still need these medicines?” It is one of the biggest misconceptions I encounter after transplant, and the answer is simple: yes. Your new liver is functioning normally because your immunosuppressive medicines are working — not because your body no longer needs them. Why that is true, and what each medicine costs in return, is what this post is about. The broader first year (clinic schedule, infection, diet, the foods and herbs that interfere with tacrolimus) is covered in life after liver transplant: the first year, and what rejection looks like and how it is treated in liver transplant rejection. Here we go deeper on the medicines themselves.

What anti-rejection medicines actually do

After transplant your immune system recognises the new liver as foreign and tries to attack it — that is rejection. Immunosuppressive medicines reduce that response and protect the graft. The liver is the most forgiving of all transplanted organs, which is why many recipients eventually manage on a single drug, but “forgiving” is not “tolerant”: withdraw the medicines and the immune system remembers what it was told to ignore.

Most recipients take a combination from four groups. The exact combination depends on your original disease, your kidney function, your rejection risk, your infection history and other individual factors — this is never one-size-fits-all.

Tacrolimus and cyclosporine: the calcineurin inhibitors

Tacrolimus is the medicine almost every recipient will know by name. It works by blocking calcineurin, a protein T cells need in order to switch on, and it is guided by a blood level drawn before the morning dose because absorption varies enormously between people — the same dose can give one patient a level too low to protect the graft and another a level high enough to damage the kidneys. Cyclosporine does the same job through the same pathway and is now used mainly in patients who cannot tolerate tacrolimus; its own signature side effects are gum overgrowth, unwanted hair growth and higher cholesterol.

The price of a calcineurin inhibitor is paid by the kidneys, the pancreas and the blood vessels. The landmark figures come from Ojo and colleagues in the New England Journal of Medicine: among 69,321 US recipients of a non-kidney organ, 16.5% developed chronic renal failure within a median of 36 months, the five-year risk ran from 7% to 21% depending on the organ, and developing it more than quadrupled the risk of death. Hence our obsession with creatinine and blood pressure at every visit, and hence the care taken over painkillers, antibiotics and anything else that stresses a kidney already under strain. Diabetes is the other large cost. A meta-analysis of 28 studies and 71,257 liver recipients put new-onset diabetes at 18.3% one year after transplant and about 25% at ten years, with higher rates in predominantly Asian cohorts — which, for an Indian patient already carrying a metabolic predisposition, means sugar is checked from the first week, not when symptoms appear.

Add a fine tremor of the hands, headaches, a tendency to raised potassium and a greater susceptibility to infection, and you have the usual tacrolimus profile. Most of it is manageable. None of it is a reason to stop the drug; all of it is a reason to tell us.

Mycophenolate: the partner drug

Mycophenolate mofetil blocks an enzyme that dividing lymphocytes depend on, so it slows the immune cells that would attack the graft without touching the kidneys the way tacrolimus does. That is its whole strategic value — it lets us run a lower tacrolimus level for the same protection. Its costs sit in the gut and the bone marrow: nausea, diarrhoea and abdominal pain, which are dose-related, and a fall in white cells or haemoglobin that shows up on the routine blood count. Infections, particularly viral ones, are more frequent when it is combined with other agents. One rule has no exceptions. Mycophenolate causes birth defects and must be stopped and replaced before a woman tries to conceive — one more reason pregnancy after transplant is planned with the team, never discovered after the fact.

Steroids: short-term workhorse, long-term liability

Prednisolone is part of almost every early regimen and intravenous methylprednisolone remains the first treatment for acute rejection, as the rejection post explains. What has changed over two decades is how long we keep patients on it. In many programmes, including ours, steroids are tapered and withdrawn within the first months unless there is a specific reason — autoimmune hepatitis, for instance — to continue a low dose. The reasons for getting off them are not cosmetic. Steroids push blood sugar up, drive weight gain and strip bone: a meta-analysis of liver recipients found new osteoporosis in about 12% and a new fracture in about 20% after transplant, with fracture risk highest in the first year, when steroid exposure is greatest and the bone has already been weakened by years of cirrhosis. The same group showed that bisphosphonate treatment cut post-transplant fractures from roughly 19% to under 7%, which is why bone density is on the monitoring list and not an afterthought.

Everolimus: the kidney-sparing alternative

Everolimus belongs to a different class — the mTOR inhibitors — and its role is defined by what tacrolimus does badly. In the pivotal randomised trial of 719 new liver recipients, adding everolimus a month after transplant and reducing the tacrolimus dose preserved kidney function better than standard tacrolimus (a difference of 8.5 mL/min in estimated filtration rate at one year) with no loss of protection against rejection. The trade-off was real: more patients stopped everolimus for side effects (26% against 14%) and serious infections were more frequent. The arm that tried to withdraw tacrolimus altogether was closed early because rejection rose. So everolimus is not a replacement; it is a tool, used in selected patients — declining kidney function, or a cancer history where tacrolimus minimisation matters — and never started in the first weeks, because it impairs wound healing. Mouth ulcers, raised lipids, protein in the urine and ankle swelling are the things we watch.

Do these medicines continue forever?

Immunosuppression is lifelong, but the regimen is not static. Doses are highest immediately after transplant, when rejection risk is greatest, and are then adjusted on the basis of liver function, kidney function, drug levels, side effects, any rejection episodes, infections and overall progress. Steroids are usually the first to go; mycophenolate is often reduced or stopped in low-risk patients later on; tacrolimus, at a lower level, is what most people are still taking at ten years.

The principle behind every one of those adjustments is the lowest effective level of immunosuppression that still protects the graft — not the highest dose “to be safe”. The evidence for that principle has sharpened. Cancer is now the leading cause of late death after liver transplant, and solid-organ recipients overall carry roughly twice the cancer incidence of the general population. A Spanish multicentre study of 2,495 tacrolimus-treated liver recipients found that cumulative tacrolimus exposure over the first year — the area under the curve of all those trough levels — was the only immunosuppression-related predictor of a later cancer, independent of which other drugs were used. Less, held steady, is safer than more. Every adjustment is individualised and made by the transplant team — never on your own.

What gets monitored, and the side effects we discuss before they become problems

Liver tests are only part of the picture. Regular monitoring also covers kidney function, blood pressure, blood sugar, cholesterol, drug levels where applicable, blood counts, signs of infection, bone health, and weight and metabolic health. Each line on that list exists because of a side effect on the table above: increased susceptibility to infection; reduced kidney function, particularly with the calcineurin inhibitors; high blood pressure; diabetes or worsening sugar control; tremor; weight gain; cholesterol changes; osteoporosis with prolonged steroid use; and a higher long-term skin cancer risk — in one prospective series, non-melanoma skin cancer occurred at about twenty times the rate of the matched general population, which is why sun protection matters more after transplant than before. Not every patient develops these, and most are manageable or preventable with regular follow-up. The ones that cause harm are the ones we hear about late.

The one mistake I never want a patient to make

Never stop, reduce or skip anti-rejection medicines without discussing it with your transplant team first.

Normal blood tests do not mean the medicines are unnecessary — they are normal because the medicines are working exactly as intended. Even a short period of missed doses can raise rejection risk, especially in the early months, and the pattern is depressingly common: a review in Liver Transplantation put non-adherence to immunosuppressants among adult recipients at 15% to 40%, with cost, side effects and the conviction that the drug was doing harm as the leading reasons. All three are conversations we can have. Halving a tablet because of tremor, stretching a prescription over a long weekend, or quietly swapping to a cheaper brand without a level check are not. If you miss a dose, contact your transplant team for guidance rather than improvising your own schedule. And since these medicines interact with many others, no new prescription, supplement or herbal product from anyone — including the dentist and the ayurvedic practitioner — without the team knowing.

A successful transplant isn’t just what happened in surgery — it is sustained by a daily partnership between you and your transplant team: medicines taken exactly as prescribed, follow-up kept, side effects reported early, nothing adjusted independently. Your transplant gave you a second chance; daily adherence is what protects it for decades. The medicines that make your new liver work are not optional once your numbers look good. They are the reason your numbers look good.

References

1. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349(10):931–940. PMID 12954741. doi:10.1056/NEJMoa021744
2. Chin YH, Tan HQM, Ng CH, et al. A time-based meta-analysis on the incidence of new onset diabetes after liver transplantation. J Clin Med. 2021;10(5):1045. PMID 33802465. doi:10.3390/jcm10051045
3. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13–58. PMID 17201457. doi:10.2165/00003088-200746010-00002
4. Lim WH, Ng CH, Ow ZGW, et al. A systematic review and meta-analysis on the incidence of osteoporosis and fractures after liver transplant. Transpl Int. 2021;34(6):1032–1043. PMID 33835638. doi:10.1111/tri.13863
5. Ho OTW, Ng WCA, Ow ZGW, et al. Bisphosphonate therapy after liver transplant improves bone mineral density and reduces fracture rates: an updated systematic review and meta-analysis. Transpl Int. 2021;34(8):1386–1396. PMID 33884669. doi:10.1111/tri.13887
6. De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012;12(11):3008–3020. PMID 22882750. doi:10.1111/j.1600-6143.2012.04212.x
7. Rodríguez-Perálvarez M, Colmenero J, González A, et al. Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation. Am J Transplant. 2022;22(6):1671–1682. PMID 35286761. doi:10.1111/ajt.17021
8. Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891–1901. PMID 22045767. doi:10.1001/jama.2011.1592
9. Herrero JI, España A, Quiroga J, et al. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transpl. 2005;11(9):1100–1106. PMID 16123952. doi:10.1002/lt.20525
10. Burra P, Germani G, Gnoato F, et al. Adherence in liver transplant recipients. Liver Transpl. 2011;17(7):760–770. PMID 21384527. doi:10.1002/lt.22294
11. Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19(1):3–26. PMID 23281277. doi:10.1002/lt.23566
12. Miedziaszczyk M, Bajon A, Jakielska E, et al. Controversial interactions of tacrolimus with dietary supplements, herbs and food. Pharmaceutics. 2022;14(10):2154. PMID 36297591. doi:10.3390/pharmaceutics14102154
13. Liu C, Shang YF, Zhang XF, et al. Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study. Eur J Clin Pharmacol. 2009;65(9):881–885. PMID 19629461. doi:10.1007/s00228-009-0702-z